U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Esophageal Adenocarcinoma

MedGen UID:
1715271
•Concept ID:
C5237825
•
Neoplastic Process

Definition

Esophageal adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Esophageal Adenocarcinoma

Professional guidelines

PubMed

Primary Surgery Not Inferior to Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Bouckaert A, Moons J, Lerut T, Coosemans W, Depypere L, Van Veer H, Nafteux P
Ann Thorac Surg 2023 Sep;116(3):571-578. Epub 2023 Mar 30 doi: 10.1016/j.athoracsur.2023.02.060. PMID: 37003580
Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West.
Moaven O, Wang TN
Surg Clin North Am 2019 Jun;99(3):479-499. Epub 2019 Mar 27 doi: 10.1016/j.suc.2019.02.004. PMID: 31047037
Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
Groth SS, Burt BM, Farjah F, Smaglo BG, Sada YH, Sugarbaker DJ, Massarweh NN
J Thorac Cardiovasc Surg 2019 Apr;157(4):1682-1693.e1. Epub 2018 Dec 15 doi: 10.1016/j.jtcvs.2018.11.131. PMID: 30711279

Recent clinical studies

Etiology

Primary Surgery Not Inferior to Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Bouckaert A, Moons J, Lerut T, Coosemans W, Depypere L, Van Veer H, Nafteux P
Ann Thorac Surg 2023 Sep;116(3):571-578. Epub 2023 Mar 30 doi: 10.1016/j.athoracsur.2023.02.060. PMID: 37003580
Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma.
Carr RA, Hsu M, Harrington CA, Tan KS, Bains MS, Bott MJ, Ilson DH, Isbell JM, Janjigian YY, Maron SB, Park BJ, Rusch VW, Sihag S, Wu AJ, Jones DR, Ku GY, Molena D
Ann Surg 2023 Mar 1;277(3):e538-e544. Epub 2021 Aug 13 doi: 10.1097/SLA.0000000000005163. PMID: 34387205Free PMC Article
CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison.
Donlon NE, Moran B, Kamilli A, Davern M, Sheppard A, King S, Donohoe CL, Lowery M, Cunningham M, Ravi N, Mueller C, Cools-Lartigue J, Ferri L, Reynolds JV
Ann Surg 2022 Nov 1;276(5):792-798. Epub 2022 Jul 25 doi: 10.1097/SLA.0000000000005617. PMID: 35876385
Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
Matsui D, Zaidi AH, Martin SA, Omstead AN, Kosovec JE, Huleihel L, Saldin LT, DiCarlo C, Silverman JF, Hoppo T, Finley GG, Badylak SF, Kelly RJ, Jobe BA
Oncotarget 2016 Dec 6;7(49):81281-81291. doi: 10.18632/oncotarget.12832. PMID: 27793030Free PMC Article
Diagnostic and therapeutic endoscopy.
Kuipers EJ, Haringsma J
J Surg Oncol 2005 Dec 1;92(3):203-9. doi: 10.1002/jso.20361. PMID: 16299782

Diagnosis

Development and validation of a molecular tool to predict pathologic complete response in esophageal adenocarcinoma.
Qian DC, Lefferts JA, Zaki BI, Brickley EB, Jackson CR, Andrici J, Sriharan A, Lisovsky M
Dis Esophagus 2022 Dec 14;35(12) doi: 10.1093/dote/doac035. PMID: 35758407
Acetic acid chromoendoscopy: Improving neoplasia detection in Barrett's esophagus.
Chedgy FJ, Subramaniam S, Kandiah K, Thayalasekaran S, Bhandari P
World J Gastroenterol 2016 Jul 7;22(25):5753-60. doi: 10.3748/wjg.v22.i25.5753. PMID: 27433088Free PMC Article
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV
Acta Oncol 2012 May;51(5):636-44. Epub 2012 Jan 2 doi: 10.3109/0284186X.2011.643822. PMID: 22208782
Role of neoadjuvant therapy for esophageal adenocarcinoma.
Ku GY, Ilson DH
Surg Oncol Clin N Am 2009 Jul;18(3):533-46. doi: 10.1016/j.soc.2009.03.004. PMID: 19500742
Diagnostic and therapeutic endoscopy.
Kuipers EJ, Haringsma J
J Surg Oncol 2005 Dec 1;92(3):203-9. doi: 10.1002/jso.20361. PMID: 16299782

Therapy

Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II Study.
Cowzer D, Wu AJ, Sihag S, Walch HS, Park BJ, Jones DR, Gu P, Maron SB, Sugarman R, Chalasani SB, Shcherba M, Capanu M, Chou JF, Choe JK, Nosov A, Adusumilli PS, Yeh R, Tang LH, Ilson DH, Janjigian YY, Molena D, Ku GY
Ann Surg 2023 Sep 1;278(3):e511-e518. Epub 2023 Feb 10 doi: 10.1097/SLA.0000000000005818. PMID: 36762546
CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison.
Donlon NE, Moran B, Kamilli A, Davern M, Sheppard A, King S, Donohoe CL, Lowery M, Cunningham M, Ravi N, Mueller C, Cools-Lartigue J, Ferri L, Reynolds JV
Ann Surg 2022 Nov 1;276(5):792-798. Epub 2022 Jul 25 doi: 10.1097/SLA.0000000000005617. PMID: 35876385
Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West.
Moaven O, Wang TN
Surg Clin North Am 2019 Jun;99(3):479-499. Epub 2019 Mar 27 doi: 10.1016/j.suc.2019.02.004. PMID: 31047037
The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Kelly RJ, Zaidi AH, Smith MA, Omstead AN, Kosovec JE, Matsui D, Martin SA, DiCarlo C, Werts ED, Silverman JF, Wang DH, Jobe BA
Ann Surg 2018 Dec;268(6):992-999. doi: 10.1097/SLA.0000000000002410. PMID: 28806299
Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome.
Yoon HH, Forastiere AA
Future Oncol 2008 Jun;4(3):413-25. doi: 10.2217/14796694.4.3.413. PMID: 18518766

Prognosis

Development and validation of a molecular tool to predict pathologic complete response in esophageal adenocarcinoma.
Qian DC, Lefferts JA, Zaki BI, Brickley EB, Jackson CR, Andrici J, Sriharan A, Lisovsky M
Dis Esophagus 2022 Dec 14;35(12) doi: 10.1093/dote/doac035. PMID: 35758407
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pericay Pijaume C, Aguado G, Martínez Lago N, Sánchez Cánovas M, Cacho Lavin D, Visa L, Martinez-Torron A, Arias-Martinez A, López F, Limón ML, Vidal Tocino R, Fernández Montes A, Alsina M, Pimentel P, Reguera P, Martín Carnicero A, Ramchandani A, Granja M, Azkarate A, Martín Richard M, Serra O, Hernández Pérez C, Hurtado A, Gil-Negrete A, Sauri T, Morales Del Burgo P, Gallego J
Gastric Cancer 2021 Jul;24(4):926-936. Epub 2021 Mar 2 doi: 10.1007/s10120-021-01169-6. PMID: 33651195
Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
Matsui D, Zaidi AH, Martin SA, Omstead AN, Kosovec JE, Huleihel L, Saldin LT, DiCarlo C, Silverman JF, Hoppo T, Finley GG, Badylak SF, Kelly RJ, Jobe BA
Oncotarget 2016 Dec 6;7(49):81281-81291. doi: 10.18632/oncotarget.12832. PMID: 27793030Free PMC Article
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV
Acta Oncol 2012 May;51(5):636-44. Epub 2012 Jan 2 doi: 10.3109/0284186X.2011.643822. PMID: 22208782
Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome.
Yoon HH, Forastiere AA
Future Oncol 2008 Jun;4(3):413-25. doi: 10.2217/14796694.4.3.413. PMID: 18518766

Clinical prediction guides

Primary Surgery Not Inferior to Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Bouckaert A, Moons J, Lerut T, Coosemans W, Depypere L, Van Veer H, Nafteux P
Ann Thorac Surg 2023 Sep;116(3):571-578. Epub 2023 Mar 30 doi: 10.1016/j.athoracsur.2023.02.060. PMID: 37003580
Development and validation of a molecular tool to predict pathologic complete response in esophageal adenocarcinoma.
Qian DC, Lefferts JA, Zaki BI, Brickley EB, Jackson CR, Andrici J, Sriharan A, Lisovsky M
Dis Esophagus 2022 Dec 14;35(12) doi: 10.1093/dote/doac035. PMID: 35758407
Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
Matsui D, Zaidi AH, Martin SA, Omstead AN, Kosovec JE, Huleihel L, Saldin LT, DiCarlo C, Silverman JF, Hoppo T, Finley GG, Badylak SF, Kelly RJ, Jobe BA
Oncotarget 2016 Dec 6;7(49):81281-81291. doi: 10.18632/oncotarget.12832. PMID: 27793030Free PMC Article
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV
Acta Oncol 2012 May;51(5):636-44. Epub 2012 Jan 2 doi: 10.3109/0284186X.2011.643822. PMID: 22208782
Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome.
Yoon HH, Forastiere AA
Future Oncol 2008 Jun;4(3):413-25. doi: 10.2217/14796694.4.3.413. PMID: 18518766

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...